PRESS RELEASES

Date	Title and Summary	Additional Formats
Toggle Summary May 9, 2018	UPDATED WITH NEW TIME*: Veracyte to Present at the 2018 UBS Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY .	View HTML PDF Version
Toggle Summary Sep 19, 2017	Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together Veracyte, Inc. and the Lung Cancer Initiative Partner to Launch New Pilot Campaign in North Carolina	View HTML Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together 26.1 KB
Toggle Summary Dec 22, 2020	Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer WHIPPANY, N.J. & SAN FRANCISCO --(BUSINESS WIRE)--Dec. 22, 2020-- Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression	View HTML PDF Version
Toggle Summary May 14, 2020	CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2020-- CareDx, Inc . (Nasdaq: CDNA) and Veracyte, Inc . (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant-rejection tests on the nCounter®	View HTML PDF Version
Toggle Summary Apr 2, 2016	Clinical Utility of Veracyte's Afirma® Gene Expression Classifier Demonstrated in Multiple Studies Presented at ENDO 2016 -- Study Advancing Genomic-Level Understanding of Hürthle Lesions Also Presented --	View HTML Clinical Utility of Veracyte's Afirma® Gene Expression Classifier Demonstrated in Multiple Studies Presented at ENDO 2016 19.3 KB
Toggle Summary Apr 23, 2020	CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis - Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 23, 2020-- Second paragraph, first sentence of release should include Dr. Jose Herazo-Maya , currently Director of Interstitial Lung Disease Program	View HTML PDF Version
Toggle Summary Nov 3, 2017	CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis Greater than 50 Percent Reduction in Patients Classified as Low Risk for Lung Cancer SAN FRANCISCO --(BUSINESS WIRE)-- Correcting quote attribution in the third paragraph of release issued Nov. 1, 2017 . The corrected release reads: VERACYTE ANNOUNCES PRESENTATION OF NEW CLINICAL UTILITY DATA AT	View HTML CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis 22.6 KB
Toggle Summary Oct 13, 2016	Data Demonstrating Clinical Value of Veracyte Genomic Tests for Use in Lung Cancer and IPF to Be Presented at CHEST Annual Meeting 2016 SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2016 /PRNewswire/ -- Veracyte, Inc. ( NASDAQ : VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that external researchers will present data from three studies	View HTML Data Demonstrating Clinical Value of Veracyte Genomic Tests for Use in Lung Cancer and IPF to Be Presented at CHEST Annual Meeting 2016 19.8 KB
Toggle Summary May 11, 2017	Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology" -- Findings suggest that test's use reduces invasive lung-cancer diagnostic procedures by 28 percent and is cost-effective --	View HTML Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology" 22 KB
Toggle Summary May 3, 2016	Data from Multiple Studies Evaluating Veracyte's Genomic Classifiers for Lung Cancer and Idiopathic Pulmonary Fibrosis to Be Presented at ATS 2016 SOUTH SAN FRANCISCO, Calif. , May 3, 2016 /PRNewswire/ -- Veracyte, Inc. ( NASDAQ : VCYT) today announced that data from multiple studies supporting the company's genomic tests to resolve ambiguity in pulmonary disease diagnosis will be presented at the American Thoracic Society (ATS) 2016	View HTML Data from Multiple Studies Evaluating Veracyte's Genomic Classifiers for Lung Cancer and Idiopathic Pulmonary Fibrosis to Be Presented at ATS 2016 23.9 KB